IL124676A0 - Improved concentrated injection and infusion solutions for intravenous use - Google Patents

Improved concentrated injection and infusion solutions for intravenous use

Info

Publication number
IL124676A0
IL124676A0 IL12467697A IL12467697A IL124676A0 IL 124676 A0 IL124676 A0 IL 124676A0 IL 12467697 A IL12467697 A IL 12467697A IL 12467697 A IL12467697 A IL 12467697A IL 124676 A0 IL124676 A0 IL 124676A0
Authority
IL
Israel
Prior art keywords
infusion solutions
intravenous use
concentrated injection
improved concentrated
injection
Prior art date
Application number
IL12467697A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL124676A0 publication Critical patent/IL124676A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452—Solutions, e.g. for injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12467697A 1996-01-25 1997-01-27 Improved concentrated injection and infusion solutions for intravenous use IL124676A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19604095 1996-01-25
PCT/DE1997/000170 WO1997026862A2 (de) 1996-01-25 1997-01-27 Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung

Publications (1)

Publication Number Publication Date
IL124676A0 true IL124676A0 (en) 1998-12-06

Family

ID=7784538

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12467697A IL124676A0 (en) 1996-01-25 1997-01-27 Improved concentrated injection and infusion solutions for intravenous use

Country Status (21)

Country Link
US (1) US6638913B1 (xx)
EP (1) EP0876140B1 (xx)
JP (1) JP2000505789A (xx)
KR (1) KR100505772B1 (xx)
CN (1) CN1209751A (xx)
AT (1) ATE251893T1 (xx)
AU (1) AU2150497A (xx)
BG (1) BG62913B1 (xx)
BR (1) BR9707081A (xx)
CA (1) CA2244209C (xx)
CZ (1) CZ234898A3 (xx)
DE (2) DE19703816A1 (xx)
DK (1) DK0876140T3 (xx)
ES (1) ES2208884T3 (xx)
HU (1) HUP9901355A3 (xx)
IL (1) IL124676A0 (xx)
NO (1) NO983438L (xx)
PL (1) PL328199A1 (xx)
PT (1) PT876140E (xx)
SK (1) SK101398A3 (xx)
WO (1) WO1997026862A2 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
ATE286743T1 (de) * 1997-10-31 2005-01-15 Us Army Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
AU751772C (en) 1998-04-01 2006-09-07 Correvio International Sàrl Aminocyclohexyl ether compounds and uses thereof
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
DK1324776T4 (en) 2000-10-12 2018-05-28 Genentech Inc CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
PL227937B1 (pl) 2003-05-02 2018-01-31 Cardiome Pharma Corp Sposób wytwarzania związku typu eteru aminocykloheksylowego, związek typu eteru aminocykloheksylowego, jego kompozycja, sposób modulowania aktywności kanałów jonowych, oraz zastosowanie związku typu eteru aminocykloheksylowego do wytwarzania leku
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US8058304B2 (en) 2004-04-01 2011-11-15 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
US7977373B2 (en) 2004-04-01 2011-07-12 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
CA2586918C (en) 2004-11-08 2021-01-19 Cardiome Pharma Corp. Use of ion channel modulating compounds for treating acute atrial fibrillation in a human
US20060270708A1 (en) * 2005-05-25 2006-11-30 Navinta Llc Novel process for preparation of isotonic aqueous injection of ropivacaine
EP1897535A1 (en) * 2006-08-30 2008-03-12 Dirinco AG Substitution fluid for haemofiltration
US20090239894A1 (en) * 2008-03-20 2009-09-24 Bjorn Schurad Stabilized aqueous solutions of ergoline compounds
KR20110128333A (ko) 2009-03-06 2011-11-29 제넨테크, 인크. 항체 제제
US9427186B2 (en) * 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
US10634741B2 (en) * 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
LT2542257T (lt) 2010-03-01 2017-11-27 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
CN102319258B (zh) * 2011-08-04 2012-10-31 山西诺成制药有限公司 一种5%葡萄糖置换液及其制备方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
CN105283202B (zh) 2013-03-11 2019-04-23 安都磁学有限公司 用于***检测的低渗溶液
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
KR20150134346A (ko) * 2013-03-27 2015-12-01 지이 헬스케어 에이에스 진단 조성물을 제조하기 위한 방법 및 시약
ES2833377T3 (es) 2015-06-04 2021-06-15 Endomagnetics Ltd Materiales marcadores y formas de localizar un marcador magnético
JP7465814B2 (ja) * 2018-04-16 2024-04-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 高濃度タンパク質製剤の粘度低下
CN110327292A (zh) * 2019-08-11 2019-10-15 天津乾丰瑞科技有限公司 一种盐酸法舒地尔注射制剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754523A (fr) * 1969-08-06 1971-02-08 Beecham Group Ltd Vaccins
BE877443A (fr) * 1978-07-04 1980-01-03 Nyegaard & Co As Procede de preparation d'unesolution tamponnee d'une substance de contraste pour rayons x
EP0077354A4 (en) * 1981-04-27 1983-09-30 Baxter Travenol Lab DIALYSIS SOLUTION CONTAINING GLUCOSE, AMINO ACIDS AND INSULIN.
ATE82500T1 (de) * 1984-06-22 1992-12-15 Richard L Veech Elektrolytloesungen und deren (in vivo) verwendung.
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
GB8906130D0 (en) * 1989-03-17 1989-05-04 Nycomed As Compositions
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
DE59007142D1 (de) 1990-01-18 1994-10-20 Cereria Amos Sgarbi Spa Grablicht.
GB9020091D0 (en) * 1990-09-14 1990-10-24 Nycomed As Contrast media
DE4135193C1 (xx) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
IT1256248B (it) * 1992-12-24 1995-11-29 Bracco Spa Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x
WO1995026331A1 (es) * 1994-03-25 1995-10-05 Centro Investigacion Justesa Imagen, S.A. Nuevos dimeros iodados no ionicos como agentes de contraste a los rayos x, metodo para su preparacion y composiciones farmaceuticas que los contienen
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung

Also Published As

Publication number Publication date
PL328199A1 (en) 1999-01-18
HUP9901355A3 (en) 2000-06-28
CN1209751A (zh) 1999-03-03
KR19990081979A (ko) 1999-11-15
BR9707081A (pt) 1999-05-25
PT876140E (pt) 2004-02-27
DE19703816A1 (de) 1997-08-07
WO1997026862A2 (de) 1997-07-31
AU2150497A (en) 1997-08-20
NO983438D0 (no) 1998-07-24
EP0876140B1 (de) 2003-10-15
WO1997026862A3 (de) 1997-10-23
BG62913B1 (bg) 2000-11-30
KR100505772B1 (ko) 2005-10-25
DK0876140T3 (da) 2003-12-15
NO983438L (no) 1998-09-18
HUP9901355A2 (hu) 1999-08-30
SK101398A3 (en) 1998-12-02
DE59710863D1 (de) 2003-11-20
BG102644A (en) 1999-06-30
EP0876140A2 (de) 1998-11-11
CA2244209A1 (en) 1997-07-31
CA2244209C (en) 2007-10-23
ATE251893T1 (de) 2003-11-15
ES2208884T3 (es) 2004-06-16
US6638913B1 (en) 2003-10-28
CZ234898A3 (cs) 1998-11-11
JP2000505789A (ja) 2000-05-16

Similar Documents

Publication Publication Date Title
IL124676A0 (en) Improved concentrated injection and infusion solutions for intravenous use
MY133569A (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
EP0935415A4 (en) METHOD FOR MAKING CONNECTIONS INTO A CELL
EP0648511A3 (de) Injektionsspritze.
ZA929225B (en) Injection syringe.
MY109880A (en) Substituted biphenylpyridones
ES2102196T3 (es) Periferializacion de celulas pluripotenciales hematopoyeticas.
EP0831871A4 (en) SIMILAR FACTOR TO RELAXIN, ITS METHODS AND USES
UA32523C2 (uk) Пептиди, які мають високу біологічну активність, та фармацевтична композиція на їх основі
GB9714564D0 (en) Composition
DK0581926T3 (xx)
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
PH31219A (en) Stable lyophilized thiotepa composition.
MY126562A (en) Pharmaceutical compositions based on dalfopristine and on quinupristine and their preparation
GR3031581T3 (en) Freeze-dried emulsion containing an active substance.
MX9602836A (es) MEZCLA QUE CONTIENE UNO O VARIOS ALFA-AMINOACIDOS Y SUS DERIVADOS, O AMBOS, Y UNO O VARIOS CICLOPENTANO- beta-AMINOACIDOS Y SUS DERIVADOS, O AMBOS.
HUP9901605A3 (en) Additive for stabilizing fuel of water content, the stabilized fuel and application thereof
EA199800819A1 (ru) Способ лечения биполярного расстройства
EP1083914A4 (en) TREATING ARTHRITIS AND OTHER SIMILAR DISORDERS
PL313594A1 (en) Triaryl ethylene derivatives for therapeutic applications
AU2768697A (en) Acyl urea compounds for the treatment of coccidioidomycosis in warm-blooded animals
ZA200107275B (en) Hypodermic injection system.
BG101526A (en) Antiphlogistic composition for external application
DE69708445D1 (de) Härtungsbeschleuniger, einen diesen beinhaltenden Injektionsschlamm und dessen Verwendung
UA32350A (uk) Спосіб лікування гострого інфаркту міокарда